Loading...
XLON
CIZ
Market cap8mUSD
Oct 09, Last price  
1.45GBP
1D
0.00%
1Q
-38.30%
IPO
-84.53%
Name

Cizzle Biotechnology Holdings PLC

Chart & performance

D1W1MN
XLON:CIZ chart
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
74.05%
Rev. gr., 5y
-55.19%
Revenues
0
222,000307,0001,628,0001,561,0002,720,0006,061,0008,701,0009,423,0007,188,0006,901,0005,319,0004,547,00074,0000000000
Net income
-691k
L+31,802.12%
-1,453,000-1,865,000-1,342,000-369,000-886,000-1,024,000-780,000-651,000-1,332,000-2,767,000000-830,000-306,000-3,920,000-910,000-1,717-2,166-691,000
CFO
-496k
L+38.55%
-1,097,000-2,095,000-1,549,000-150,000-305,000-1,510,000-145,000-678,000-526,000-570,000186,000-190,000-513,000-7,072-294,000-1,009,000-872,000-639,000-358,000-496,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Cizzle Biotechnology Holdings Plc specializes in developing an advanced immunoassay diagnostic test. This innovative tool aims to identify the CIZ1B biomarker, facilitating the early detection of lung cancer. The company, previously known as Cizzle Biotechnology Limited, officially changed its corporate identity to Cizzle Biotechnology Holdings Plc in May 2021. Its main operational base is situated in London, United Kingdom.

Key people

Dawn Coverley
Chief Scientific Officer, Executive Director · since 2025
Nigel Lee
Finance Director, Executive Director · since 2021
Allan Syms
Executive Chairman of the Board · since 2021
Matt Bower
Non-Executive Director · since 2025
Edwin Matthew
Non-Executive Director · since 2025
John Treacy
Non-Executive Independent Director · since 2021
URL
https://cizzlebiotechnology.com/
IPO date
May 23, 2007
Employees
4
Domiciled in
GB
Incorporated in
GB
Headquarters & legal address
C/O AMPA HOLDINGS LLP
LEVEL 19, THE SHARD
32 London Bridge Street
LONDON, LND SE1 9SG
GB
Previous name
BOULD OPPORTUNITIES PLC
Previous name
PHOTONSTAR LED GROUP PLC

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT